Contact us on +44 (0)1270 270010 | info@boydconsultants.com

Xanamem™ identified as a good candidate to investigate for the treatment of Alzheimer’s disease – Phase I data published in the British Journal of Pharmacology

Xanamem™ identified as a good candidate to investigate for the treatment of Alzheimer’s disease – Phase I data published in the British Journal of Pharmacology
February 10, 2017 boydsads17

The research paper, Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™) has been published in the British Journal of Pharmacology (BJP).

Highlights

The research paper, which was co-authored by Alan Boyd, reports that Phase I results show Xanamem™ is safe and well tolerated with no major safety issues. The paper also confirms the brain penetrating properties of Xanamem™ and that it reaches the brain at concentrations predicted to inhibit excess cortisol production in the brain; and that Xanamem™ is a good candidate to further investigate as a treatment for Alzheimer’s disease.

Reducing glucocorticoid exposure in the brain via intracellular inhibition of the cortisol-regenerating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has emerged as a therapeutic strategy to treat cognitive impairment in early Alzheimer’s disease (AD).

Boyds has been actively involved in the study working closely with Actinogen and Edinburgh University, with Alan Boyd providing medical support.

To read the full research paper, click here.